11. Follow Up and Monitoring

11.1 Category 1: Possible Alzheimer’s Disease.

Patients diagnosed with possible Alzheimer’s disease will be followed up for a period of one year with repeat cognitive and clinical assessments, to facilitate the establishment of a more definitive diagnosis of Alzheimer’s disease or resolve any ambiguity regarding the diagnosis.

11.2 Category 2: Mild Cognitive Impairment.

MCI participants will be followed up annually until they transition to dementia or for a period of 3 years with annual cognitive and clinical assessments or until a clinical diagnosis of dementia can be confirmed from repeat cognitive and clinical assessments. Dementia and dementia subtype will be defined according to standard criteria (DSM IV-R).

11.3 Category 3: Early Onset Neurodegeneration.

Early onset neurodegeneration participants will be followed up annually until they transition to dementia or for a period of 3 years with annual cognitive and clinical assessments or until a clinical diagnosis of dementia can be confirmed from repeat cognitive and clinical assessments. Dementia and dementia subtype will be defined according to standard criteria (DSM IV-R).

11.4 Repeat Assessments- Year 2 & Year 3.

Each participant will be subject to a repeat consenting process for Year 2 and Year 3 physiological assessments (LP and blood draw – Consent Form 2,3,4) and at this time patients must retain the capacity to provide informed consent for this repeat testing.